^
    Back
    Association details:
    Biomarker:PILRA overexpression
    Cancer:Lung Adenocarcinoma
    Drug Class:PD-L1 inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Front Genet
    Title:

    Identification of Novel Prognostic Biomarkers Relevant to Immune Infiltration in Lung Adenocarcinoma

    Published date:
    04/27/2022
    Excerpt:
    High expression levels of PSTPIP1 and PILRA were associated with longer overall survival and rich immune infiltration in LUAD patients, and both were significantly high in patients who responded to anti–PD-L1 treatment.
    DOI:
    https://doi.org/10.3389/fgene.2022.863796